NCT05615532View on ClinicalTrials.gov

A Relative Bioavailability Study of LY3209590 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

168

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions

Healthy

Interventions

DRUG

LY3209590 (SC)

Administered SC.

DRUG

LY3209590 (IV)

Administered IV.

Trial Locations (1)

138623

Lilly Centre for Clinical Pharmacology, Singapore

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY